Keeping up with Dementia Research - Monthly Roundups by Iris
Dementia Research news, once a month, in about five minutes: Alzheimer's disease clinical trials, dementia drug approvals, blood biomarkers for dementia, neurodegeneration mechanisms and genetics, dementia risk factors and prevention, and dementia care research. Every story links to its sources.
Latest: September 2026
FDA clears PrecivityAD2 for adults as young as 40
- FDA cleared C2N's PrecivityAD2 for symptomatic adults aged 40 and older, with supporting evidence that it improved primary-care diagnostic accuracy from 65% to 93%:
- Acadia's remlifanserin Phase 2 RADIANT topline narrowly missed its primary endpoint, met a key secondary endpoint and leaves both Phase 3 studies continuing:
- A meta-analysis found modest lecanemab-related cognitive benefits alongside a substantially higher risk of ARIA-E, while a real-world cohort showed treatment-associated plasma proteins moving in four different directions:
Want this for your field?
Iris builds a briefing agent around your own profile: your field, your focus areas, your context. Delivered on your schedule.